The 18th Annual Conference on Retroviruses and Opportunistic Infections (CROI) wrapped up in Boston, Massachusetts, earlier this month, and UNC had a strong presence at this year’s conference.
The University of North Carolina at Chapel Hill School of Medicine has launched a new program which will expand both the research and clinical capabilities of the University.
UNC researchers Jeff Dangl, PhD, and P. Frederick Sparling, MD, have been named fellows of the American Academy of Microbiology
Fellows are elected in recognition of excellence, originality and creativity in the microbiological sciences, and have built exemplary careers in basic and applied research, teaching, clinical and public health, industry or government service.
William Messer, MD, PhD has been awarded a career development award from the Southeast Regional Center of Excellence for Emerging Infections & Biodefense (SERCEB). Messer is a third-year infectious diseases fellow in the Division of Infectious Diseases at the UNC School of Medicine.
A small number of people with HIV have the ability to control the infection without therapy. They don’t develop clinical disease, are less likely to transmit HIV to others and the number of key infection fighting cells in their immune system remains stable.
Myron Cohen, MD, and Ron Swanstrom, PhD , were recently appointed to prestigious HIV/AIDS advisory council positions. Dr. Cohen will sit on the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Research Advisory Committee and Swanstrom will take a position on the Office of AIDS Research Advisory Council (OARAC) under the National Institutes of Health (NIH).
Investigators at the University of North Carolina at Chapel Hill comprise one of 12 scientific teams in more than a dozen states which will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.
The HIV and Clinical Trials 101 lecture series, which took place August 23-31, targets new research and clinical staff in the Division of Infectious Diseases and is an update on current practices related to HIV/AIDS.
September 2, 2010 -- David Margolis, MD, professor of medicine, was interviewed by Simeon Bennett of Bloomberg Buisnessweek for his rearch using a cancer drug to kill HIV virus that lurks in patients receiving antiretroviral therapy. The story appears on the Bloomberg News website. A slightly different version appears in the print edition of Businessweek.
By Anne McNulty (’11)
The flu kills more than 35,000 people in the United States in an average year—and most of those deaths could be prevented with a simple vaccine. After last year’s H1N1 outbreak, the government says everyone over the age of 6 months needs a flu shot this year.
August 19, 2010 – The virus that causes AIDS may undergo changes in the genital tract that make HIV-1 in semen different than what it is in the blood, according to a study led by researchers from the University of North Carolina at Chapel Hill.
Myron Cohen, MD, addresses a satellite session on the implications of an important microbicides trial at the International AIDS Society conference
New results and next steps are the focus of the year’s most important HIV/AIDS research gathering. UNC researchers present findings on antiretroviral drugs, prevention approaches and community interventions.
UNC study: Antiretroviral drugs for mothers, nevirapine syrup for babies both effective in preventing HIV transmission through breast milk
UNC Study reveals that giving antiretroviral drugs to HIV-infected breastfeeding mothers in sub-Saharan Africa or giving an HIV-fighting syrup to their babies are both effective.
A crucial alternative to doctor monitoring in light of shortage of health care workers around the world